High Yields 2018 Qs Flashcards
How does the PD-1/PD-L1 interaction relate to tumor growth?
TEST QUESTION
Programmed cell death protein 1 (PD-1) is a transmembrane protein expressed on T cells, B cells, and natural killer (NK) cells. It has an inhibitory effect and binds to the programmed cell death ligand 1 and 2.
PDL-1 is expressed on the surface of multiple tissue types, including many tumor cells, as well as hematopoietic cells.
PD-1 is the negative regulator of cell activation.
The tumor microenvironment up-regulates PD-1 on tumor reactive T cells, and contributes to impaired antitumor immune responses (the PD-1/PDL-1 intercation inhibits apoptosis of the tumor cell)
- PD-1 inhibitors:
Nivolumab
Pembrolizumab
Cemiplimab
Dostarlimab
Retifanlimab
Toripalimab
Tislelizumab
PDL-1 inhibitors:
Atezolizumab
Avelumab
Durvalumab
CTLA-4 inhibitors:
Ipilimumab
Tremelimumab
what are Interferons?
non specific immune modulators named for interfering with viral machinery
*INF Gamma upregulates PD-1 and PDL-1. It is also an important activator of macrophages and inducer of major histocompatibility complex class II molecule expression.
what part of the Her2 receptor is the target of intervention? (ie: Intracellular, tyrosine kinase, extracellular, transmembrane)
extracellular portion
What is the other name for protein Ca125?
The gene for CA 125 is called MUC16 or mucin16
What distinguishes PSTT from choriocarcinoma?
1.INTERMEDIATE trophoblasts
2.Human Placenta Lactogen
3. Lower betaHCG
*all of these
What distinguishes endometrial stromal nodule (ESN) from low grade endometrial stromal sarcoma (LG-ESS)?
A ESS has more mitoses
B ESS has more atypia
C presence of spiral arterioles
D absence of LVSI in ESN
Absence of LVSI is the correct answer choice
The histologic features of ESN are identical to LG-ESS but ESN has a circumscribed, noninfiltrating border without evidence of myometrial or vascular invasion. ESN is a benign neoplasm that is cured with simple hysterectomy.
B&H: Because diagnosis is based on complete circumscription and absence of lymphovascular invasion, the distinction between stromal nodule and stromal sarcoma can usually be made only at the time of hysterectomy.
Ratio of tumor markers for ovca and colon cancer?
CA125/CEA (this one, 25:1), HE4/CEA
Picture of pap serous uterine cancer histology
pap serous
other test options that are wrong: LMS, endometrioid
Architecture:
Papillary with or without appreciable fibrovascular cores; micropapillary pattern can be seen
Slit-like spaces
Gland-like spaces may be observed
Psammoma bodies may be present in up to 33% of cases
Cytoplasm usually scant but can be abundant with eosinophilia or clearing
Tumor cells can colonize existing endometrial glands
Tumor cells can appear discohesive
Nuclei are typically high grade with pleomorphism, hyperchromasia, prominent nucleoli and frequent mitotic figures (including atypical mitotic figures)
Napsin A (IHC stain)
clear cell carcinoma
- Immunophenotype: most often lacks estrogen receptors and WT-1. Do have: p53 expression, napsin-A, hypoxia-inducible factor 1 alpha (HIF-1 alpha), glypican-3, and hepatocyte nuclear factor 1-beta (HNF-1 beta).
POLE mutated (group 1)
excellent prognosis regardless of grade POLE (why? high tumor mutation burden, tumor neoantigen production, and tumor infiltrating T cells)
MSI hypermutated (group 2)
Most common methylation of MLH1; also can have mutated MLH1, MSH2, MSH6, PMS2; MLH1 + PMS2, MSH2 + MSH6 form dimers so if one degraded the other is; immunotherapy candidates if recurrent; radiation beneficial
High TMB ≥10 mutations/megabase > pembrolizumab.
dMMR/MSI-H: pembrolizumab or dorstalimab.
Tumors without dMMR or high TMB: Pembrolizumab plus lenvatinib
MSS/copy number low (group 3 - PTEN, ARID1A, PIK3CA mut, ER/PR pos)
Good prognosis; respond to hormonal therapy; PI3K/mTOR inhibitors for metastatic disease
Copy number high (group 4) of endometrial cancer molecular subgroup is most likely what histology?
serous; p53 mutated; poor prognosis; trastuz if HER2 +/ERBB2 amp
what are the most common MMR defects in Hnpcc?
MLH1/MSH2 (this one); PMS2, MSH6
MLH1 and MSH2 genes are by far the most commonly mutated in Lynch syndrome patients accounting for ~70% of the mutations identified (32% in MLH1 and 38% in MSH2)
KRAS associations?
Type 1 ovary tumors, mucinous histology ; also recurrent low grade serous carcinoma (unlike BRAF)
Integrin role in cancer?
metastases role (cell invasion and migration)
adhesion of leukocytes to endothelial cells
Mechanism of ERBB2 oncogenicity?
AMPLIFICATION of oncogene producing HER2 protein
How do kinases work?
Phosphorylation
*Tyrosine kinases are enzymes that selectively phosphorylates tyrosine residue in different substrates. Receptor tyrosine kinases are activated by ligand binding to their extracellular domain. Ligands are extracellular signal molecules (e.g. EGF, PDGF etc) that induce receptor dimerization (except Insulin receptor) and a cascade of events.
Which of the following is a tumor site not included in risk for HNPCC ?
A breast
B gastric
C pancreatic
D urethral
E brain
“breast // does include endometrial, colon, gastric, ovarian, pancreatic, urethral, brain (glioblastoma), small intestinal,
sebaceous gland adenomatous polyps, keratoacanthomas
Histopath of leiomyosarcoma?
List 3
-prominent cellular atypia
-abundant mitoses (≥10 per 10 high power fields)
-areas of coagulative necrosis
*Two of these are necessary for a diagnosis
Grade 1 endometrioid, young, normal weight - tumor most likely to express:
A MSH2
B CK7
C ER
D PR
MSH2
Germ cell tumor least likely to have elevated AFP
Dysgerminoma and choriocarcinoma both not elevated
Genetic mut associated with type I endometrial cancer
PTEN (PTEN tumor suppressor is the most important negative regulator of PI3K signaling)
How does Loss of heterozygosity occur (two mechanisms)
Deletion (most common) or methylation
*Loss of heterozygosity: refers to a type of mutation that results in the loss of one copy of a segment of DNA
*LOH occurs when a cancer cell that is originally heterozygous at a locus loses one of its two alleles at that locus, either by simple deletion of one allele (copy-loss LOH), or by deletion of one allele accompanied by duplication of the remaining allele (copy-neutral LOH). When a cancer cell undergoes LOH of an essential gene, further loss or inhibition specifically of the allele retained in the tumor should not be tolerated, whereas normal cells will be able to survive relying solely on the remaining allele